Upregulated circRNA_100269 suppresses the growth and metastasis of gastric cancer by inactivating PI3K/Akt signaling pathway

Abstract

Background: The expression of circRNA_100269 in gastric cancer (GC) tissues and cells, together with its regulatory roles on GC cells were investigated.

Methods: The levels of circRNA_100269 in GC and matched para-carcinoma tissues, as well as in human GC cell lines and normal gastric epithelial cells were evaluated using RT-qPCR. The models with overexpression or knockdown of circRNA_100269 were generated using lentiviral vectors. Cell viability was examined using MTT assay; cell migration and invasive activity were determined by wound healing and Transwell assay. Cell cycle arrest and apoptosis were assessed; molecules involved in PI3K/Akt signaling, apoptosis and EMT were evaluated using RT-qPCR and immunoblotting. Tumour growth and expression of relevant proteins were examined in circRNA_100269 knockout mice.

Results: The results indicated the expression of circRNA_100269 was dramatically decreased in GC samples compared with para-carcinoma tissues (p < 0.05), while the levels of PI3K were notably increased (p < 0.05). Moreover, the level of circRNA_100269 was relevant to histology grade and occurrence of metastasis in GC patients (p < 0.05), where circRNA_100269 and PI3K was inversely correlated (p < 0.05). Additionally, circRNA_100269 was downregulated in GC cells compared with normal gastric epithelial cells. Overexpressed circRNA_100269 remarkably suppressed the proliferation, migration, invasion and EMT of GC cells (p < 0.05), induced cell cycle arrest at G0/G1 phase and promoted cell apoptosis (p < 0.05). In addition, PI3K/Akt signaling was involved in circRNA_100269-mediated proliferation, migration, invasion, EMT and apoptosis in GC cells (p < 0.05). Knockdown of circRNA_100269 also significantly promoted tumor growth in vivo (p < 0.05).

Conclusions: the data of the present study suggested that the expression level of circRNA_100269 was decreased in GC tissues and cells. In addition, circRNA_100269 inhibited the progression of GC by suppressing PI3K/Akt signaling. Therefore, circRNA_100269/PI3K/Akt axis may be a potential therapeutic target for GC treatment.

Background

Gastric cancer (GC) is a type of aggressive tumor and one leading cause of cancer-related mortality, and the incidence of GC are rising worldwide (1). The pathogenesis of GC is complex, and previous study has revealed that the five-year survival rate of GC patients in China remains poor (~ 25–30%; 2). Recently, therapeutic approaches for GC have been developed and endoscopic/surgical resection is broadly used for patients with GC; however, the prognosis of GC is still poor. The therapeutic outcome of patients with GC is relevant to disease staging at diagnosis, and the mortality of patients with advanced GC remains high (~ 30–50%; 3–5). Nevertheless, the molecular mechanisms during the onset and development of GC are still unclear. Thus, it is essential to identify putative diagnostic and prognostic biomarkers for this disease.

Circular RNAs (circRNAs) are a group of new non-coding RNAs. Not like their linear counterparts, they can form a continuous circle which is characterized with a more stable structure (6–8). Due to the absence of free 5'- or 3'- overhangs in the structure, circRNAs are resistant to the degradation caused by exonuclease (6). Furthermore, the distributions of circRNAs are tissue specific (8). Some circRNAs have been revealed as putative gene regulators, the regulatory functions of most circRNAs are not fully understood (9). Recent studies have revealed that circRNAs could be able to exert their function as miRNA ‘sponges’ which competitively suppress the activity of corresponding miRNAs (10). In addition, circRNAs are involved in the initiation and development of numerous diseases, including nervous system disorders and tumour (11–13). For instance, previous research has revealed the regulatory functions of a novel circRNA SFMBT2 in GC, and it could act as a sponge for miR-182-5 p to regulate the growth of tumour (14). Furthermore, recent report revealed downregulation of circRNA_100269 in GC, which inhibits tumor growth through regulating miR-630 (15). However, the detailed functions of circRNA_100269 have not been reported. Therefore, the regulatory roles and novel molecular targets of circRNA_100269 in GC were still elusive and require further elucidation.

Previous research suggested that miR-630 is associated with the regulation of various biological processes including EMT through numerous pathways such as PI3K/Akt signaling (16, 17). PI3K can be activated by oncogenes, consequently activated PI3K is capable of promoting the growth and metastasis of tumour cells (18). Akt is a downstream molecule of PI3K, and it is associated with numerous biological processes, such as cell proliferation, invasion and EMT (19). The activation of Akt could induce the migration, invasion and EMT of cancer cells (20). Activation of PI3K/Akt could contribute to upregulated migratory/invasive abilities of human osteosarcoma cells (21). Therefore, inhibition of PI3K/Akt pathway could be a novel therapeutic strategy for cancer treatment. In our study, the effects of circRNA_100269-modulated PI3K/Akt signaling on the growth and metastasis of GC cells were investigated. The data suggested that cell cycle was arrested at G0/G1 phase and cell apoptosis was promoted in GC cells overexpressing circRNA_100269, where the levels of p-Akt and Bcl-2 were also notably reduced. These data suggested that overexpressed circRNA_100269 could inhibit the proliferation, migration and invasion while inducing the cell cycle arrest and apoptosis of GC cells via PI3K/Akt signaling. Our data could provide novel insight on the treatments of GC.

Materials And Methods

Clinical samples. A total of 56 matched GC and non-tumour samples (≥ 5 cm from tumor margin; 26 males and 30 females; aged 40–78 years old) were collected during surgery at the First Affiliated Hospital of Jinzhou Medical University (Jinzhou, China) from July 2010 to June 2013. The tissues were sectioned and snapfrozen using liquid nitrogen post-surgery, and stored at 80˚C. The patients were divided into circRNA_100269 high- or low-expression group was according to the mean value of circRNA_100269 expression. All the biopsies were evaluated by two independent pathologists, and the clinicopathological features of recruited patients were presented in Table I. Overall survival rates were obtained by Kaplan-Meier method. Written informed consents were signed by the patients, and all the samples were anonymized. The present study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Jinzhou Medical University.

Cell culture. Four human GC cell lines (AGS, SGC-7901, BGC-823 and MKN-45) and one normal human gastric epithelial cell line (GES-1) were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained using DMEM containing 10% fetal bovine serum (FBS), 100 µg/ml streptomycin and 100 U/ml penicillin (HyClone; GE Healthcare Life Science), and cultured at 37˚C in a incubator supplied with 5% CO₂.

Cell transfection. To establish the cell model overexpressing circRNA_100269, wildtype (o/e-circRNA_100269) or mutant (o/e-NC) circRNA_100269 sequence was amplified using PCR, then subcloned into pcDNA3.1 vector (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). In circRNA_100269 knockdown model, shRNA sequences against circRNA_100269 (sh-circRNA_100269) or negative control (sh-NC) were obtained from Genepharm Co. Ltd. (Shanghai, China). Following annealing, shRNA were inserted in lentiviral pU6-Luc-Puro vector (Genepharm Co. Ltd.). Cells without any shRNA treatment were used as the control group. Up- or downregulation of circRNA_100269 was examined by RT-qPCR. All the transfections were performed using Lipofectamine®2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Eight hours following transfection, culture media were replenished with fresh DMEM supplemented with 10% FBS. For the inhibition of PI3K signalling, cells were treated with LY294002 (10µM; Cell Signaling Technology, Beverly, USA).

RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA from clinical samples or cells was extracted by TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and then reverse transcribed into cDNA by a PrimeScript™ RT kit (Takara Biotechnology Co., Ltd., Dalian, China). The target cDNA was amplified using SYBR Green PCR Master Mix (TaKaRa Biotechnology Co., Ltd.), which was carried out using an ABI 7500 Real-Time PCR system (Thermo Fisher Scientific, Inc.) Endogenous GAPDH was used as internal control. The sequences of forward and reverse primer were as follows: circRNA_100269, 5’-CTATGTCGTTCAAGGAAGA-3’ and 5’-GTCTTGAGACTGGGTATGT-3’; PI3K, 5’-AACACAGAAGACCAATACTC-3’ and 5’-TTCGCCATCTACCACTAC-3’; E-cad, 5’-AAGAAGCTGGCTGACATGTACGGA-3’ and 5’-CCACCAGCAACGTGATTTCTGCAT-3’; vimentin, 5’-AGAACCTGCAGGAGGCAGAAGAAT-3’ and 5’-TTCCATTTCACGCATCTGGCGTT-3’; snail, 5’-TTTCTGGTTCTGTGTCCTCTGCCT-3’ and 5’-TGAGTCTGTCAGCCTTTGTCCTGT-3’; Bax, 5’-TAATCCCAGCGCTTTGGAA-3’ and 5’- TGCAGAGACCTGGATCTAGCAA-3’; cas-9, 5’-CATTTCATGGTGGAGGTGAAG-3’ and 5’-GGGAACTGCAGGTGGCTG-3’; MMP9, 5’-CAGAGATGCGTGGAGAGT-3’ and 5’-TCTTCCGAGTAGTTTTGG-3’; GAPDH, 5’-GCAAGAGCACAAGAGGAAGA-3′ and 5’-ACTGTGAGGAGGGGAGATTC-3’. PCR program was 95˚C for 5 min, followed by 45 cycles of 95˚C for 15 s, 60˚C for 20 s and 72˚C for 10 s. Relative expression was determined using 2^−∆∆Cq method.

Western blotting. Total protein was extracted by radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Shanghai, China). The concentration of extracted protein was determined using bicinchoninic acid assay (Beyotime Institute of Biotechnology). Equal amount (30 µg) of samples were loaded on SDS-PAGE gel and subsequently transferred onto a PVDF membrane (EMD Millipore, Billerica, MA, USA). Membranes were blocked using tris-buffered saline (TBS) with 5% skimmed milk at room temperature for 2 h and incubated using correspondent primary antibodies: PI3K (1:2000; cat. no. ab140307; abcam), Akt (1:1000; cat. no. 9272; Cell Signaling Technology), p-Akt^S473 (1:1000; cat. no. 4058; Cell Signaling Technology), p53 (1:1000, cat. no. 9282; Cell Signaling Technology), Bcl-2 (1:1000, cat. no. 15071; Cell Signaling Technology), cyclin D1 (1:2000, cat. no. 2926; Cell Signaling Technology), E-cad (1:1000, cat. no. 3195; Cell Signaling Technology), vimentin (1:2000; cat. no. 5741; Cell Signaling Technology), snail (1:1000; cat. no. 3879; Cell Signaling Technology), Bax (1:1000; cat. no. 2772; Cell Signaling Technology), cas-9 (1:2000; cat. no. 14697; Cell Signaling Technology), MMP9 (1:1000; cat. no. 3852; Cell Signaling Technology) or GAPDH (1:1,000; cat. no. sc-47724; Santa Cruz Biotechnology Inc.) at 4˚C overnight. The membranes were subsequently incubated with corresponding horseradish peroxidase-conjugated anti-mouse (1:5,000; cat. no. sc-2371; Santa Cruz Biotechnology Inc.) or anti-rabbit IgG (1:5000; cat. no. sc-2357; Santa Cruz Biotechnology Inc.) at room temperature for 1 h. Protein bands were visualized by an enhanced ECL protein detection kit (Pierce Biotechnology; Thermo Fisher Scientific, Inc). Signals were quantified using densitometric method by Image J software (NIH, Bethesda, MD, USA).

Cell proliferation assay. Cells were harvested 24 h post-transfection, and 1 × 10⁴ cells were placed in 96-well plates. The proliferation of cells was examined using MTT assay (Sigma-Aldrich; Merck KGaA) at day 1, 2, 3 and 4. Briefly, 20 µl of MTT solution was added into each well and incubated at 37˚C for 4 h, the absorbance at 450 nm was detected using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Wound healing assay. Cells were seeded onto 6-well plates at a density of 4 × 10⁵ cells/well and transfected with corresponding vectors. After the cells reached the confluency of 80–100%, the cell monolayer was scratched in a straight line with a sterile micropipette tip and washed three times with PBS, which was replaced with fresh DMEM. Subsequently, the scratch width changes were observed immediately following the scratch and at 6, 12 and 24 h. The images were captured using a fluorescence microscope (magnificationx100, Olympus Corporation, Tokyo, Japan). The migration of cells was determined by ImageJ 6.0 using the following formula: Migration area ratio = proportion of closed wound area/entire field of view area.

Transwell assay. A total of 1 × 10⁵ cells were suspended using FBS-free culture medium and seeded onto the Matrigel^®-pre-coated (Sigma-Aldrich, St. Louis, MO, USA) upper chamber (BD Biosciences, Franklin Lakes, New Jersey, USA). Subsequently, 500 µl of culture medium containing 10% FBS was added into the lower chamber. Following overnight incubation, non-invasive cells were detached using a cotton swab, while invaded cells in the lower chamber were fixed using 4% paraformaldehyde and stained by 0.5% crystal violet. The numbers of invasive cells were counted in five randomly selected fields using an inverted light microscope (magnificationx200, Olympus Corporation, Tokyo, Japan).

Cell cycle and apoptosis analysis. Cells were inoculated onto 6-well plates with a density of 4 × 10⁵ cells/well following the treatments with o/e-circRNA_100269 or o/e-NC, respectively. Then, cells were collected using low-speed centrifugation (1000 rpm) at 4˚C for 5 min. Cell pellets were rinsed and re-suspended in PBS, subsequently fixed with 70% pre-chilled ethanol and stored at 4˚C for two days. Cells were lysed prior to flow cytometry, centrifuged and then re-suspended using propidium iodide (PI, Sigma-Aldrich, USA) staining buffer containing 50 µl/ml of PI with 250 µl/ml RNase A. Cell cycle distributions were determined by a flow cytometer (BD Biosciences, USA) and then analysed using Flowjo version 7.6 software (Flowjo LLC, USA). To evaluate cell apoptosis, the suspended cells was incubated in dark at 4˚C for 30 min and stained with 5 µl annexin V-FITC (JingMei Biotech, Beijing, China), and apoptosis was examined using a a flow cytometer (BD Biosciences, USA) and then analysed using Flowjo version 7.6 software (Flowjo LLC, USA).

In vivo nude mouse xenograft. Female BALB/C nude mice (4-5-week-old) with the weight of ~ 19 g were purchased from The Laboratory Animal Research Centre of Nantong University (Nantong, China). The mice were routinely housed in a temperature-controlled environment (22 ± 2˚C) with 60% relative humidity, under a 12-h dark/light cycle with libitum access to food and water for at least three days before the experiments. Mice were randomly grouped (n = 5 in each group) and injected with AGS cells transfected with sh-NC or sh-circRNA_100269. Briefly, a total of 1 × 10⁷ cells were suspended in 200 µl PBS and injected into the back subcutaneously. Mice with developing tumors were monitored four times a week. Six weeks post-injection, the mice were sacrificed, and the tumor tissues were removed and examined. Tumor volume was calculated as follows: V (mm³) =(length x width²)/2. To initiate metastasis, 1 × 10⁵ cells were suspended in 20 µl PBS and then injected in the lateral tail vein of mice. Experiments contained 10 mice inoculated with tumor cells on day 0. Followed injection, mice were randomly sorted into experimental groups to be evaluated after 42 days. The protocol of animal experiment was approved by the Ethics Committee of our Hospital.

Statistical analysis. Data were presented as means ± standard error of mean and analysed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). The significance of differences was analysed using one-way analysis of variance (ANOVA) or the Student’s t-test. A student-Newman-Keuls test was carried out after ANOVA. The association between RNA expression was determined using Spearman’s correlation analysis. P < 0.05 was considered to indicate a statistically significant difference.

Results

The expression of circRNA_100269 is reduced in GC tissues and cells. The expression levels of circRNA_100269 were determined in 56 paired GC and non-tumour tissues using RT-qPCR. The data suggested that circRNA_100269 was significantly downregulated in GC samples compared to para-carcinoma controls (Fig. 1A). Additionally, the relationship between circRNA_100269 and the development of GC was evaluated, and the results indicated that circRNA_100269 was notably reduced in patients with advanced GC (Fig. 1B). Additionally, the expression of circRNA_100269 was remarkably downregulated in GC patients with metastasis (Fig. 1C). Moreover, GC patients with relatively low levels of circRNA_100269 exhibited significantly reduced overall survival (p = 0.0025, log-rank test; Fig. 1D). Similarly, downregulation of circRNA_100269 was also detected in GC cells comparing to normal gastric epithelial cells (Fig. 1E). Taken all together, the level of circRNA_100269 was decreased in GC, which may lead to the progression of tumour.

Overexpression of circRNA_100269 suppresses the growth, metastasis and EMT of GC cells. In order to investigate the effects of circRNA_100269 on the progression of GC, circRNA_100269 was overexpressed in AGS and MKN-45 cells. The transfection efficiencies were evaluated by RT-qPCR (Fig. 2A). Furthermore, the data of MTT assay revealed that the viabilities of GC cells transfected with o/e-circRNA_100269 was suppressed (Fig. 2B and C). Would healing assay was performed to evaluate cell migration, whereas invasive activity was determined using transwell assay. Our data revealed that cell migration/invasion was inhibited within the circRNA_100269 overexpression group compared with the control (Fig. 2D-G). To investigate the effects of overexpressed circRNA_100269 on EMT of GC cells, the protein and mRNA levels of associated molecules such as E-cad, vimentin and snail were evaluated. The expression of abovementioned proteins were affected in cells transfected with o/e- circRNA_100269 (Fig. 2H and I). In summary, overexpressed circRNA_100269 may result in suppressed proliferation, migration, invasion and EMT of GC cells.

Overexpressed circRNA_100269 promotes cell cycle arrest and apoptosis in GC cells. According to the abovementioned results, circRNA_100269 was able to affect the proliferation and metastasis of GC cells. Furthermore, to investigate the influences of overexpressed circRNA_100269, the distribution of cell cycle and apoptosis in GC cells transfected with o/e-circRNA_100269 were evaluated compared with the control. The results revealed that GC cell cycle was dramatically shifted from S and G2/M phase to G0/G1 phase, and the cell percentage in G0/G1 phase was significantly increased, whereas those in S phase was notably reduced (Fig. 3A and B). Furthermore, the results of flow cytometry revealed that overexpressed circRNA_100269 also promoted the apoptosis of GC cells (Fig. 3C and D), which was confirmed by the upregulation of apoptosis-related markers including Bax, Cas-9 and MMP9 (Fig. 3E and F). Our findings suggested that upregulation of circRNA_100269 could arrest cell cycle in G0/G1 phase to induce cell apoptosis.

Knockdown of circRNA_100269 induces the development of GC cells. As part of gain- and loss-of-function study, circRNA_100269 was knockdown in GC cells. The efficiencies of shRNA were confirmed by RT-qPCR (Fig. 4A). MTT assay indicated that the cell viabilities were increased following the transfection with sh- circRNA_100269 (Fig. 4B and C). The results of wound healing and transwell assays revealed that cell migrating and invasive abilities were enhanced in GC cells transfected with sh-circRNA_100269 (Fig. 4D-G). Furthermore, the levels of EMT-related molecules were influenced in sh-circRNA_100269 transfected group (Fig. 4H and I). Taken all together, knockdown of circRNA_100269 could lead to enhanced proliferation, migration, invasion and EMT within GC cells.

Knockdown of circRNA_100269 suppressed cell cycle arrest and apoptosis in GC cells. To study the effects of downregulated circRNA_100269 on cell cycle distribution and apoptosis, further experiments were performed. The results suggested that cell percentage in G0/G1 phase was remarkably reduced, whereas that in S phase was notably increased (Fig. 5A and B). Additionally, the results of flow cytometry indicated that downregulated circRNA_100269 expression inhibited the apoptosis of GC cells (Fig. 5C and D), which was also confirmed by the downregulation of apoptosis-associated markers (Fig. 5E and F). In summary, these findings revealed that knockdown of circRNA_100269 could inhibit cell cycle arrest and apoptosis in GC.

PI3K/Akt signaling pathway is the novel target of circRNA_100269 in GC. Further experiments were conducted to investigate the mechanisms of circRNA_100269-modulated cell growth and apoptosis in GC. Western blot analysis indicated that overexpressed circRNA_100269 was able to downregulate the expression levels of PI3K and phosphorylated Akt (p-Akt), while knockdown of circRNA_100269 enhanced the expression of PI3K and p-Akt (Fig. 6A). Moreover, the downstream targets of PI3K/Akt signaling such as p53, Bcl-2 and cyclin D1 were examined. As presented in western blotting, the protein levels of Bcl-2 and cyclin D1 were decreased, whereas p53 was increased in GC cells overexpressing circRNA_100269, and vice versa. In addition, the levels of PI3K were evaluated in GC and para-carcinoma tissues. The results revealed significant upregulation of PI3K in GC samples compared with normal controls (Fig. 6B). Moreover, the expression of PI3K was notably increased in patients with advanced GC (Fig. 6C), and the level of PI3K was remarkably upregulated in GC patients with metastasis (Fig. 6D). Additionally, the expression levels of PI3K and circRNA_100269 were inversely correlated (Fig. 6E). Furthermore, the level of PI3K was notably elevated in GC cell lines (Fig. 6F). Our data indicated that circRNA_100269 could affect the development of GC by regulating PI3K/Akt pathway.

Inhibition of PI3K/Akt signaling reverses the biological behavior changes caused by circRNA_100269 in GC cells. To study whether the influences of circRNA_100269 on the progression of GC cells was modulated through PI3K/Akt pathway, GC cells were transfected by sh-NC, sh-circRNA_100269 or co-treated with LY294002. The results indicated that the effects caused by downregulated circRNA_100269 in GC cells were abolished by inactivation of PI3K/Akt signaling (Fig. 7). These findings revealed that PI3K/Akt signaling is involved in circRNA_100269-mediated cell growth and metastasis in GC, suggesting circRNA_100269 could suppress the development of GC by suppressing PI3K/Akt pathway.

Knockdown of circRNA_100269 promotes the progression of GC in vivo. To study if sh-circRNA_100269 promotes the development of GC, cells transfected with sh-circRNA_100269 or the control were injected in BALB/C nude mice subcutaneously. Six weeks following the inoculation, mice were sacrificed. Tumor tissues were isolated and examined (Fig. 8A). The average tumor volume of sh-circRNA_100269 group was notably increased (Fig. 8B). In addition, the tumor weight of circRNA_100269 knockout mice was significantly elevated (Fig. 8C). Additionally, the numbers of macroscopic nodules were remarkably elevated in sh-circRNA_100269 mice (Fig. 8D). Moreover, the results of western blot analysis suggested that EMT-, apoptosis- and PI3K/Akt-associated markers exhibited the same expression pattern as observed in the in vitro assays (Fig. 8E). The results suggested that knockdown of circRNA_100269 could promote the development of GC by inhibiting PI3K/Akt signaling in vivo.

Discussion

GC is a common type of malignancy that is a major cause of cancer-related mortality (1, 2). Although the recent treatments of GC have been developed, the therapeutic outcome of this disease still remains poor (3–5). Accumulating evidences have suggested that circRNAs are associated with tumourigenesis of numerous types of cancer (11–13). Furthermore, aberrant levels of circRNAs has been found in tumour cells, indicating the potential roles of circRNAs during the development of cancer including GC. Among these lncRNAs, circRNA_100269 was downregulated in GC, which functions as tumor suppressor through regulating miR-630 (15). Furthermore, miR-630 serves essential roles during EMT via various pathways including PI3K/Akt signaling (16, 17). However, the exact functions and downstream molecular targets of circRNA_100269 in GC were not completely understood and require further investigation. Thus, our findings could provide novel insight on the therapeutic development of GC. The activation of PI3K could be triggered by oncogenes, consequently resulting in the development of tumour (18). Akt is a downstream molecule of PI3K, which is associated with cell growth and EMT, and activated Akt could promote the migration, invasion and EMT of cancer cells such as osteosarcoma cells (19–21). Therefore, inactivation of PI3K/Akt signaling could be a putative therapeutic strategy for cancer treatment.

In this study, the effects of circRNA_100269-modulated PI3K/Akt axis on the growth and metastasis of GC were elucidated. Our results revealed significant downregulation of circRNA_100269 in GC patients, whereas the levels of PI3K were remarkably elevated, and their expression were correlated with the tumour grading and occurrence of metastasis. In addition, downregulated circRNA_100269 and upregulated PI3K were detected in GC cells. Overexpressed circRNA_100269 notably inhibited the growth, metastasis and EMT of GC cells, and vice versa. Furthermore, our data also suggested cell cycle was arrested at G0/G1 phase and cell apoptosis was promoted in GC cells overexpressing circRNA_100269, where the expression levels of PI3K/Akt-associated molecules were also affected, suggesting the biological behavior changes in GC cells caused by circRNA_100269 could be dependent on PI3K/Akt signaling. Knockdown of circRNA_100269 significantly promoted tumour development both in vitro and in vivo. These data suggested that circRNA_100269 could inhibit the proliferation, migration and invasion while inducing the cell cycle arrest and apoptosis of GC cells by suppressing PI3K/Akt signaling pathway. In consistence with our findings, recent studies also reported circRNAs including circNHSL1 and circNF1 could be novel gene regulators in GC, which can affect tumour progression through various signaling pathways (22–27). Taken all together, our results revealed the essential roles of circRNA_100269/PI3K/Akt signaling on the modulation of GC progression.

Conclusion

In summary, our results suggested that circRNA_100269 was a promising target for tumor suppression that could inhibit the development of GC by targeting PI3K/Akt pathway. These data revealed the key functions of circRNA_100269 and the potential mechanisms underlying the growth and metastasis of GC, which provided substantial evidences on the roles of circRNA_100269 in tumourogenesis. At present, inhibition of PI3K/Akt signaling is considered as a potential therapeutic approach in cancer treatment (28–33). CircRNA_100269/PI3K/Akt axis could be a putative therapeutic target for the treatment of GC.

Abbreviations

circRNAs: circular RNAs; GC: gastric cancer

Declarations

Acknowledgements

Not applicable.

Funding

This study was supported by the Natural Science Foundation of Liaoning Province (grant no. 20170540401).

Availability of data and materials

The datasets generated in our present study are included in this published article.

Authors’ contributions

CL initiated the research. ZW and CL carried out the experiments and analysed the data. Both authors drafted the manuscript, then reviewed and approved the final version.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of the First Affiliated Hospital of Jinzhou Medical University (Jinzhou, China). Written informed consent was signed by all patients.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–31.
2. Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385:977–1010.
3. Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–49.
4. Park Y, et al. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011;25(8):2666–77.
5. Choi, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center experience. Surg Endosc. 2013;27(11):4250–8.
6. Memczak S, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495:333–8.
7. Salzman J, Gawad C, Wang P, Lacayo N, Brown P. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. Plos One. 2012;7:e30733.
8. Conn S, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015;160:1125–34.
9. Vicens Q, Westhof E. Biogenesis of Circular RNAs Cell. 2014;159:13–4.
10. Hansen T, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–8.
11. Yao Z, Luo J, Hu K, et al. ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. Mol Oncol. 2017;11(4):422–37.
12. Li J, Song Y, Circular. RNA GLI2 promotes osteosarcoma cell proliferation, migration, and invasion by targeting miR-125b-5p. Tumour Biol. 39(7), 2017.
13. You X, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18:603–10.
14. Sun H, et al. Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression. Cancer Manag Res. 2018;16(10):5725–34.
15. Zhang Y, Liu H, Li W, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630. Aging. 2017;9(6):1585–93.
16. Feng J, Wang X, Zhu W, Chen S, Feng C. MicroRNA-630 suppresses Epithelial-to-Mesenchymal Transition by regulating FoxM1 in gastric cancer cells. Biochemistry. 2017;82(6):707–14.
17. Sun Y, et al. MiR-630 inhibits Endothelial-Mesenchymal Transition by targeting slug in traumatic heterotopic ossification. Scientific reports. 2016;6:2272–85.
18. Yang L, Liu Y, Wang M, Qian Y, Dai X, Zhu Y, Chen J, Guo S, Hisamitsu T. Celastrus orbiculatus extract triggers apoptosis and autophagy via PI3K/Akt/mTOR inhibition in human osteosarcoma cells. Oncol Lett. 2016;12:3771–8.
19. He F, Chen H, Yang P, Wu Q, Zhang T, Wang C, Wei J, Chen Z, Hu H, Li W, Cao J. Gankyrin sustains PI3K/GSK-3beta/beta-catenin signal activation and promotes osteosarcoma aggressiveness and progression. Oncotarget. 2016;7:81156–71.
20. Fan X, Wang Y, Wang L, Zhu M. Salidroside induces apoptosis and autophagy in human osteosarcoma cells through inhibition of PI3K/Akt/mTOR pathway. Oncol Rep. 2016;36:3559–67.
21. Qian D, Xiao X, Byun J, Suriawinata A, Her S, Amos C, Barth R. PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic osteosarcoma. Clin Cancer Res. 2017;23:399–406.
22. Fang X, Wen J, Sun M, et al. CircRNAs and its relationship with gastric cancer. J Cancer. 2019;10(24):6105–13.
23. Wang Z, Ma K, Pitts S, et al. Novel circular RNA circNF1 acts as a molecular sponge, promoting gastric cancer by absorbing miR-16. Endocr Relat Cancer. 2019;3(26):265–77.
24. Shi P, Wan J, Song H, Ding X. The emerging role of circular RNAs in gastric cancer. Am J Cancer Res. 2018;8(10):1919–32.
25. Wang K, Dong M. Role of circular RNAs in gastric cancer: Recent advances and prospects. World J Gastrointest Oncol. 2019;11(6):459–69.
26. Zhu Z, Rong Z, Luo Z, et al. Circular RNA circNHSL1 promotes gastric cancer progression through the miR-1306-3p/SIX1/vimentin axis. Molecular Cancer. 2019;18:126–35.
27. Shan C, Zhang Y, Hao X, et al. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Molecular Cancer. 2019;18:136–45.
28. Alexander W. Inhibiting the Akt pathway in cancer treatment. Pharmacy therapeutics. 2011;36:225–7.
29. Nitulescu G, Margina D, Tsatsakis A, et al. Akt inhibitors in cancer treatment: The long journey from drug discovery to clonical use. Int J Oncol. 2015;48:869–85.
30. Brown J, Banerji U. Maximizing the potential of Akt inhibitors as anti-cancer treatments. Pharmocol Ther. 2017;172:101–15.
31. Jansen V, Mayer I, Arteaga C. Is there a future for Akt inhibitors in the treatment of cancer? 22: 2599–2601, 2016.
32. Mayer I, Arteaga C. The PI3/Akt pathway as a target for cancer treatment. Annual review of medicine. 2016;67:11–28.
33. Suvarna V, Murahari M, Khan T. Phytochemicals and PI3K inhibitors in cancer-an insight. Front Pharmacol. 2017;8:1–23.

Table

Table I. Clinical and pathological characteristics of patients with GC enrolled in the present study.